

UCD School of Medicine Scoil an Leighis UCD

Mater Misericordiae University Hospital

# Assessment of Associations between Markers of Renal Function and Bone Mineral Density in HIVpositive and HIV-negative Subjects



HRB Health Research Board



<u>E. Alvarez</u><sup>1</sup>, A.G. Cotter<sup>1,2</sup>, C. Sabin<sup>3</sup>, J. O'Halloran<sup>1,2</sup>, J.J. Brady<sup>4</sup>, C. Galvin<sup>4</sup>, A. Macken<sup>1</sup>, E. Kavanagh<sup>5</sup>, G. McCarthy<sup>6</sup>, P.W.G. Mallon<sup>1,2</sup>, HIV UPBEAT Study Group

<sup>1</sup>University College Dublin School of Medicine, HIV Molecular Research Group, Dublin, Ireland, <sup>2</sup>Mater Misericordiae University Hospital, Department of Infectious Diseases, Dublin, Ireland, <sup>3</sup>University College London Medical School, Research Department of Infection&Population Health, London, United Kingdom, <sup>4</sup>Mater Misericordiae University Hospital, Department of Clinical Chemistry and Diagnostic Endocrinology, Dublin, Ireland, <sup>5</sup>Mater Misericordiae University Hospital, Department of Radiology, Dublin, Ireland, <sup>6</sup>Mater Misericordiae University Hospital, Department of Rheumatology, Dublin, Ireland.

Corresponding author: Elena Alvarez elena.alvarezbarco@ucd.ie

# Introduction

HIV infected individuals have higher prevalence of renal disease and low bone mineral density (BMD) compared with HIV uninfected controls <sup>1-3</sup>. Renal dysfunction may induce bone damage as a secondary effect, but the relationship between these pathologies remains poorly understood.

# Aims

We aimed to determine relationships between specific markers of renal function and bone parameters.

## Results

#### Renal and Bone function

Average, serum renal and bone parameters were within normal range, with no differences in prevalence of abnormal parameters between HIV-positive and HIVnegative subjects.

However, there were higher P/Cr and RBP/Cr ratios in the HIV-positive group compared with the control group (all p<0.001) (Table 2).

The HIV-positive group showed a significantly higher bone turnover and lower BMD compared with the control group (all p<0,001), in agreement with previous results from the entire UPBEAT cohort<sup>3</sup>.

#### Table 2. Urinary parameters of renal function

N=419	HIV-positives (N=169)	HIV-negatives (N=250)	p
Protein			
P/Cr (mg/mmol)	8.6 (6.7-14.2)	6.3 (5.0-9.5)	<0.0001
P/Cr >15	28 (17)	8 (3)	<0.0001
RBP/Cr (µg/g)	105.29 (68.1-192.4)	71.51 (50.7-108.4)	<0.0001
Abnormal RBP/Cr*	62 (37)	26 (11)	<0.0001
Phosphate			
TmP/GFR (mmol/L)	1.02 (0.8-1.3)	1.01 (0.9-1.2)	0.23
Abnormal TmP/GFR	24 (15)	26 (11)	0.36
Glucose			
Uglucose>1 (mmol/L)	2 (1.2)	5 (2)	0.70

## **Methods**

Cross-sectional analysis of the HIV UPBEAT cohort, comparing HIV-positive and HIV-negative subjects from similar demographic backgrounds.

We collected demographic and clinical history, including regional dual X-ray absorptiometry (DXA) from the UPBEAT clinical database.

Renal/ bone profile and bone turnover markers (BTMs) from fasting blood samples and protein, creatinine, phosphate and glucose from fresh frozen urine samples.

We further estimated the renal function using:

- eGFR-MDRD4: Normal >90mL/min/1.73m<sup>2</sup>
- Protein/creatinine ratio (P/Cr): Normal <15 mg/mmol
- Retinol binding protein/Creatinine ratio: (RBP/Cr) Normal <130 µg/g if age<50 and <172 µg/g if age>50
- Maximal reabsorption capacity of phosphate (TmP/GFR): Normal >0.8 mmol/L

## Statistical analysis:

- Descriptive statistics: median, interquartile range (IQR) and absolute (percentage frequencies)
- Between-groups differences: Mann-Whitney/Student's t test and Chi-squared tests (Fisher's exact test)
- Relationships between renal markers and bone parameters: Spearman correlation methods
- Independent associations between markers of renal function and bone parameters: univariate/multivariable linear regression models adjusted for demographic / life style factors and BMI (model 1), HIV-status (model 2) and laboratory variables including BTMs (model 3).

# Results


A total of 419 subjects with available urine sample at baseline were included in the analysis.

\*Abnormal RBP/Cr: RBP/Cr >130  $\mu$ g/g if age<50 and >172  $\mu$ g/g if age>50.

## Associations between renal and bone parameters

Higher RBP/Cr ratio significantly correlated with lower LS-, FH-, and TH-BMD (r=-0.183, r=-0.204, r=-0.193, all p<0.001). Patients with abnormal RBP/Cr had significantly lower BMD at each site (Figure 1). Similar associations were found between P/Cr ratio and BMD at the 3 sites (r=0.173, r=-0.163, r=-0.171, respectively).

## Figure 1. BMD at each site according to RBP/Cr and P/Cr values



On univariate testing, RBP/Cr, P/Cr and HIV status were associated with reduced BMD at FN, LS and TH (all p<0.0001). In addition, African ethnicity, current smoking, third education level and lower BMI were all associated with lower BMD at the 3 anatomical sites.

After adjustment for demographic /life-style factors and BMI (model 1, Table 3), RBP/Cr but not P/Cr was independently associated with lower BMD at FN, LS and TH with the association remaining robust with further adjustment for HIV-status (model 2, Table 3). Further adjustment for laboratory parameters (parathyroid hormone and alkaline phosphatase) and BTMs (model 3, Table 3) minimally abrogated the effect of RBP/Cr on BMD whereas the effect of HIV on BMD was largely reduced.

Table 3. Parameter estimates (coefficients B) and 95% confidence interval (95%CI) from multivariate linear regression models exploring relationships of RBP/Cr, P/Cr and HIV infection with BMD at FN, LS and TH.

BMD_FN (g/cm²)	Model 1 B	95% CI	р	Model 2 B	95% CI	p	Model 3 B	95% CI	p
RBP/Cr (per20 µg/g↑)	-0.006	-0.011, -0.003	0.003	-0.005	-0.008, -0.001	0.01	-0.004	-0.007, -0.001	0.04
P/Cr (per5mg/mmol↑)	-0.002	-0.005, 0.001	0.13	-	-	-	-	-	-
HIV-positive status	-0.073	-0.107, -0.040	<0.0001	-0.063	-0.098, -0.029	<0.0001	-0.015	-0.053, 0.023	0.30
BMD_LS (g/cm <sup>2</sup> )	В	95% CI	ρ	В	95% CI	p	В	95% CI	p
RBP/Cr (per20 µg/g↑)	-0.006	-0.010, -0.002	0.001	-0.006	-0.010, -0.002	0.006	-0.005	-0.009, -0.001	0.02
P/Cr (per5mg/mmol↑)	-0.003	-0.006, 0.001	0.12	-	-	-	-	-	-
HIV-positive status	-0.074	-0.112, -0.035	<0.0001	-0.064	-0.103, -0.026	0.001	-0.021	-0.066, 0.023	0.34
BMD_TH (g/cm²)	В	95% CI	р	В	95% CI	p	В	95% CI	p
RBP/Cr (per20 µg/g↑)	-0.005	-0.009, -0.001	0.010	-0.004	-0.007, 0.000	0.048	-0.003	-0.006, 0.001	0.12
P/Cr (per5mg/mmol↑)	-0.001	-0.004, 0.001	0.35	-	-	-	-	-	-
HIV-positive status	-0.084	-0.116, -0.052	<0.0001	-0.081	-0.114, -0.047	<0.0001	-0.035	-0.073, 0.002	0.06

Patient characteristics are detailed in Table 1.

Within the HIV-positive group, the median (IQR) time since HIV diagnosis was 5 (2-8) years, median (IQR) CD4+ T-cell count was 476 (350-653) (cells/mm<sup>3</sup>), 89% were currently on ART of whom 78% had undetectable RNA-HIV (<50 copies/mL).

#### Table 1. Baseline characteristics

N=419 N(%)	HIV-positives (N=169)	HIV-negatives (N=250)	р
Male	103 (60.9)	111 (44.4)	0.001
African ethnicity	61 (36.7)	64 (25.6)	0.01
Age (years)*	39 (33-47)	42 (35-49)	0.02
BMI (kg/m²)*	26 (23-29)	27 (25-30)	0.005
HCV-coinfection	15 (8.8)	3 (1.2)	<0.0001
Hypertension	31 (25)	43 (21)	0.41
Diabetes	2 (1.2)	3 (1.2)	0.35
Current smoker	68 (40.2)	38 (15.2)	<0.0001
Current alcohol	98 (57.9)	189 (75.6)	<0.0001

\* Median (IQR). BMI: body mass index; HCV: hepatitis C virus.

## Discussion

The excretion of protein in urine was the only parameter significantly different between HIV-positive and HIV-negative subjects.

Tubular proteinuria, measured by RBP/Cr, but not total proteinuria, is associated with reduced BMD at the 3 anatomical sites. This association persists even correcting for by HIV infection and BTMs.

Further studies are needed to understand the mechanisms underlying this association and the contribution of specific HIV-related factors to alterations in renal and bone parameters.

## **References and Acknowledgements**

1.Shcouten J. et al.CID 2014; 2. Brown TT, Qaqish RB. AIDS 2006; 3. Cotter AG et al., AIDS 2014

This work was supported by the Irish Health Research Board who funded A.G.C. (award HRA\_POR/2010/66) and an unrestricted grant awarded to P.W.G.M by GlaxoSmithKline Ltd. We would like to thank the patients of the Infectious Diseases Clinic at the Mater Misericordiae University Hospital, Dublin, Ireland, and the healthy volunteers who contributed to the study.